Previous close | 76.91 |
Open | 76.94 |
Bid | 77.74 x 900 |
Ask | 79.00 x 2900 |
Day's range | 76.81 - 78.43 |
52-week range | 53.22 - 78.43 |
Volume | |
Avg. volume | 15,525,191 |
Market cap | 173.62B |
Beta (5Y monthly) | 0.54 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.42 |
Earnings date | 27 Apr 2022 - 02 May 2022 |
Forward dividend & yield | 2.16 (2.85%) |
Ex-dividend date | 31 Mar 2022 |
1y target est | 79.16 |
Bristol Myers (BMY) phase III CheckMate -901 study fails to meet the primary endpoint of overall survival in patients with untreated unresectable or metastatic urothelial cancer.
PRINCETON, N.J., May 16, 2022--BMS Provides Update on CheckMate -901 Trial
BridgeBio (BBIO) forms an exclusive partnership with Bristol Myers (BMY) to develop and commercialize its SHP2 inhibitor.